## **Vagus Nerve Stimulation**

Medicare National Coverage Determination (NCD) 160.18 Checklist			
	NCD 160.18 MM11461	Patient Name: MR:	
Effective Date: For services performed on or after 2/15/2019			
/agus Nerve Stimuations (VNS) is a pulse generator, similar to a pacemaker, that is surgically implanted under the skin of the left chest and an electrical lead (wire) is connected from the generator to the left vagus nerve. Electrical signals are sent from the battery-powered generator to the vagus nerve via the lead. These signals are in turn sent to the brain. For treatment of TRD, it is subcutaneously connected to an electrode attached to the left vagus nerve in the neck.			
GENERAL REQUIREMENTS			
	VNS device is FDA approved for treatment of refractory epilepsy or resistant depression.		
	VNS is an outpatient procedure.		
	Diagnoses (ICD-10) code reflecting qualifying condition (see coverage indications). Examples include:  • G40.011 Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, with status epileptic  • G40.019 Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, without status epilepticus		
COVERAGE INDICATIONS			
Vagus Nerve Stimulation IS considered medically reasonable and necessary for the following:			
	Patient with medically refractory partial onset seizures for whom surgery either has failed or is not recommended		
	2. <u>Patient mee</u> • must be in a the most cu • depressive i • with a majo • maintained • If with bipol 3. <u>Patient doe</u> • current or lij • current secuent or verent or verent or verent or verent or verent or verent or vere	th resistant depression under Coverage Evidence Development (CED) in the CMS-approved, double-blind, randomized, placebo-controlled clinical trial * see below link  Note: Individuals who receive placebo VNS will be offered active VNS at the end of the trial.  *https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/VNS - trial details and enrollment info  ets the following criteria: In major depressive disorder (MDD) episode for ≥ two years or have had at least four episodes of MDD, including the current episode. To confirm MDD, use accepted diagnostic criteria from rent edition of the Diagnostic and Statistical Manual for Mental Disorder (DSM) and a structured clinical assessment;  Illness meets a minimum criterion of four prior failed treatments of adequate dose and duration as measured by a tool designed for this purpose; Ir depressive episode (MDE) as measured by a guideline recommended depression scale assessment tool on two visits, within a 45-day span prior to implantation of the VNS device; In a stable medication regimen for at least four weeks before device implantation; and ar disorder, the condition is carefully characterized; It is not have: If the individuals who receive placebo VNS will be offered active VNS device previously implanted for any approved treatment/clinical trial not required.	
	_	nosis codes or CED-related coding not required required, attesting to the reasonable and necessary need for the replacement device based off NCD160.18 criteria	
	NONCOVERED INDICATIONS		
Agus Nerve Stimulation is <u>NOT</u> covered for treatment of: - All other types of seizure disorders which are medically refractory and for whom surgery is not recommended or for whom surgery has failed - Resistant depression when furnished outside of a CMS-approved CED study - Depression (all other indications)			

Checklist completed by:

Date:

Disclaimer: The content of the checklists were created as an educational tool. Use of these documents are not intended as a replacement for the documentation requirements published in National or Local Coverage Determinations, or the CMS's documentation guidelines, written law or regulations. Medicare policy changes frequently; Providers/Departments are reminded to review current National and Local Coverage Determination and Policy Articles for specific documentation and coding guidelines.

Compliance Services Created: 06/25/20